Ignite Creation Date:
2024-05-06 @ 6:25 PM
Last Modification Date:
2024-10-26 @ 2:47 PM
Study NCT ID:
NCT05652920
Status:
RECRUITING
Last Update Posted:
2024-04-03
First Post:
2022-11-27
Brief Title:
Ori-C101Chimeric Antigen Receptor CAR Modified T Cells for the Treatment of HCC
Sponsor:
OriCell Therapeutics Co Ltd
Organization:
OriCell Therapeutics Co Ltd
Study Overview
Official Title:
A Phase IbII Open-Label Multi-Center Study to Investigate the Safety PK and Efficacy of Ori-C101 in Advanced Hepatocellular Carcinoma HCC Patients BEACON
Status:
RECRUITING
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a Phase I open-label multi-center study to assess the safety pharmacokinetics and preliminary efficacy of GPC3-directed chimeric antigen receptor modified T cells injection Ori-C101 in Advanced Hepatocellular CarcinomaHCC
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None